SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

Follicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually characterised by a typically indolent clinical course, with a median survival rate o...

Descripción completa

Detalles Bibliográficos
Autores: Provencio Pulla, M., Alfaro Lizaso, J., Cruz Merino, Luis de la, Gumá i Padró, J., Quero Blanco, C., Gómez Codina, J., Llanos Muñoz, M., Martínez Banaclocha, N., Rodriguez Abreu, D., Rueda Domínguez, A.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/156646
Acceso en línea:https://hdl.handle.net/11441/156646
https://doi.org/10.1007/s12094-015-1437-1
Access Level:acceso abierto
Palabra clave:Oncohematology malignancies
Follicular non-Hodgkin’s lymphoma
Non-Hodgkin lymphoma therapy
id ES_bab5dbfcabd6c7f2df58314082cc1e3d
oai_identifier_str oai:idus.us.es:11441/156646
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphomaProvencio Pulla, M.Alfaro Lizaso, J.Cruz Merino, Luis de laGumá i Padró, J.Quero Blanco, C.Gómez Codina, J.Llanos Muñoz, M.Martínez Banaclocha, N.Rodriguez Abreu, D.Rueda Domínguez, A.Oncohematology malignanciesFollicular non-Hodgkin’s lymphomaNon-Hodgkin lymphoma therapyFollicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually characterised by a typically indolent clinical course, with a median survival rate of 8–10 years, although most patients relapse after treatment. Diagnosis should always be based on a surgical specimen like an excisional node lymph biopsy. The first-line treatment of FL will depend of extension disease, tumour burden, patient symptoms, performance status and also patient decision. The addition of rituximab to conventional chemotherapy has improved ORR, PFS and OS. As first line in patients that need treatment, a combination of chemotherapy with rituximab induction followed by 2 years of rituximab maintenance is the best option. High-dose chemotherapy with autologous stem-cell transplantation in first line has not shown improvement and is not recommended as first line therapy. Before any treatment decision in relapsed patients, a repeat biopsy is mandatory to rule out a trans formation into large cell aggressive lymphoma. Standard treatment is controversial, depends on the efficacy of prior treatment, duration of the time-to-relapse, patient’s age and histological findings at relapse.SpringerMedicinaCTS151: Bioquímica médica2015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/156646https://doi.org/10.1007/s12094-015-1437-1reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésClinical and Translational Oncology, 17 (12), 1014-1019.https://link.springer.com/article/10.1007/s12094-015-1437-1info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1566462026-06-17T12:51:07Z
dc.title.none.fl_str_mv SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
title SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
spellingShingle SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
Provencio Pulla, M.
Oncohematology malignancies
Follicular non-Hodgkin’s lymphoma
Non-Hodgkin lymphoma therapy
title_short SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
title_full SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
title_fullStr SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
title_full_unstemmed SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
title_sort SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
dc.creator.none.fl_str_mv Provencio Pulla, M.
Alfaro Lizaso, J.
Cruz Merino, Luis de la
Gumá i Padró, J.
Quero Blanco, C.
Gómez Codina, J.
Llanos Muñoz, M.
Martínez Banaclocha, N.
Rodriguez Abreu, D.
Rueda Domínguez, A.
author Provencio Pulla, M.
author_facet Provencio Pulla, M.
Alfaro Lizaso, J.
Cruz Merino, Luis de la
Gumá i Padró, J.
Quero Blanco, C.
Gómez Codina, J.
Llanos Muñoz, M.
Martínez Banaclocha, N.
Rodriguez Abreu, D.
Rueda Domínguez, A.
author_role author
author2 Alfaro Lizaso, J.
Cruz Merino, Luis de la
Gumá i Padró, J.
Quero Blanco, C.
Gómez Codina, J.
Llanos Muñoz, M.
Martínez Banaclocha, N.
Rodriguez Abreu, D.
Rueda Domínguez, A.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
CTS151: Bioquímica médica
dc.subject.none.fl_str_mv Oncohematology malignancies
Follicular non-Hodgkin’s lymphoma
Non-Hodgkin lymphoma therapy
topic Oncohematology malignancies
Follicular non-Hodgkin’s lymphoma
Non-Hodgkin lymphoma therapy
description Follicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually characterised by a typically indolent clinical course, with a median survival rate of 8–10 years, although most patients relapse after treatment. Diagnosis should always be based on a surgical specimen like an excisional node lymph biopsy. The first-line treatment of FL will depend of extension disease, tumour burden, patient symptoms, performance status and also patient decision. The addition of rituximab to conventional chemotherapy has improved ORR, PFS and OS. As first line in patients that need treatment, a combination of chemotherapy with rituximab induction followed by 2 years of rituximab maintenance is the best option. High-dose chemotherapy with autologous stem-cell transplantation in first line has not shown improvement and is not recommended as first line therapy. Before any treatment decision in relapsed patients, a repeat biopsy is mandatory to rule out a trans formation into large cell aggressive lymphoma. Standard treatment is controversial, depends on the efficacy of prior treatment, duration of the time-to-relapse, patient’s age and histological findings at relapse.
publishDate 2015
dc.date.none.fl_str_mv 2015
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/156646
https://doi.org/10.1007/s12094-015-1437-1
url https://hdl.handle.net/11441/156646
https://doi.org/10.1007/s12094-015-1437-1
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clinical and Translational Oncology, 17 (12), 1014-1019.
https://link.springer.com/article/10.1007/s12094-015-1437-1
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417941270790144
score 15.812455

Similares en LA Referencia